International consensus guidance for management of myasthenia gravis
Sanders, Donald B. (Duke University Medical Center)
Wolfe, Gil I. (Duke University Medical Center)
Benatar, Michael (University at Buffalo School of Medicine and Biomedical Sciences, State University of New York; Department of Neurology)
Evoli, Amelia (University of Miami, Miller School of Medicine (FL, Estats Units d'Amèrica). Department of Neurology)
Gilhus, Nils E. (Catholic University (Roma, Itàlia). Department of Clinical Medicine)
Illa, Isabel (Institut d'Investigació Biomèdica Sant Pau)
Massey, Janice M. (Duke University Medical Center)
Kuntz, Nancy (Duke University Medical Center)
Melms, Arthur (Northwestern Feinberg School of Medicine (Chicago, Estats Units d'Amèrica))
Murai, Hiroyuki (University of Tübingen (Alemanya). Department of Neurological Therapeutics)
Nicolle, Michael (Kyushu University (Fukuoka, Japó). Department of Clinical Neurological Sciences)
Palace, Jacqueline (Western University (London, Canadà). Department of Clinical Neurology)
Richman, David P. (John Radcliffe Hospital (Oxford, Regne Unit))
Verschuuren, Jan (University of California (Davis, Estats Units d'Amèrica). Department of Neurology)
Narayanaswami, Pushpa (Leiden University Medical Centre (Leiden, Països Baixos))
Universitat Autònoma de Barcelona

Fecha:	2016
Resumen:	To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.
Nota:	Altres ajuts: Supported by a grant from the Myasthenia Gravis Foundation of America (MGFA).
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	Neurology, Vol. 87 (july 2016) , p. 419-425, ISSN 1526-632X

DOI: 10.1212/WNL.0000000000002790
PMID: 27358333

7 p, 189.2 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados